•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
SeekingAlpha
50%
Yahoo
50%
Country
US
Industry
Health Care
Market Cap
Small Cap
Num. Employees
38
IPO Date
Apr 13, 2006
Country
US
Industry
Health Care
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 38 full-time employees. The company went IPO on 2006-04-13. The firm is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The Company’s lead compound ANAVEX2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066, a mixed sigma-1/sigma-2 ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer.
GuruFocus has detected 1 Warning Sign with AVXL.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Related Stocks
Related Stocks
Stocks being mentioned with AVXL
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data